Regenxbio Inc

This non-binding advisory proposal asks shareholders to approve the compensation of the Company’s named executive officers as disclosed in the proxy. Management seeks this advisory endorsement to validate its pay programs and show alignment with stockholder interests; the Board’s recommendation “For” indicates confidence in the design and governance of executive pay. Compensation is overseen by an independent Compensation Committee supported by Willis Towers Watson; pay elements include base salary, short-term cash incentives tied to corporate and individual objectives, and long-term equity (options/RSUs and newly introduced PSUs). For 2025, the Company emphasized performance-linked incentives with corporate goals weighted heavily (CEO’s cash incentive based entirely on corporate objectives) and incorporated optional equity mix choices for NEOs to increase alignment. The vote is advisory and non-binding, but the Board commits to consider results and stockholder feedback when setting future compensation. Key contextual factors include the Company’s clinical-stage status, reliance on milestone-driven progress (non-financial performance measures often more relevant than net income for biotech), and recent corporate events affecting pay decisions (e.g., partnership and financing transactions). Potential stockholder concerns could include the size and mix of awards, retention-related grants, and severance/change-in-control protections; management’s response emphasizes independent oversight, benchmarking, and clawback policies. A sophisticated analyst should weigh the advisory vote within the broader governance context—committee independence, use of performance metrics tied to program milestones, and the Company’s stage of development—when assessing whether pay is appropriately calibrated to shareholder value creation and risk.

This management proposal requests approval for a structured option-for-option exchange for non-executive employees intended to restore incentive value, improve retention, and reduce option overhang. Management argues the program is less dilutive and more cost-effective than granting additional equity or increasing cash compensation, and it excludes executive employees and directors to align with investor and proxy-advisor expectations; a separate proposal (Proposal 5) covers executives. The exchange is limited to options with exercise prices at or above $18.00 and outstanding for at least two years, with tiered exchange ratios developed using Black‑Scholes valuation to achieve approximate fair-value neutrality; replacement options vest over two years (50% at one year, remainder at two) and have an eight-year term. If fully subscribed, management estimates a net reduction in option overhang (e.g., 1,620,107 net shares in the non-executive exchange), which would modestly decrease potential future dilution and free shares for future grants under the 2025 Equity Incentive Plan. From an accounting perspective, incremental compensation expense will be measured as the excess of replacement option fair value over surrendered option fair value and is expected to be immaterial, recognized over the vesting period; tax treatment is expected to be non-taxable at grant because replacement exercise prices equal fair market value. Governance considerations include that participation is voluntary, tender-offer rules will apply, and employees terminating before grant retain original awards but cannot participate—both retention and selection mechanics merit review. Potential investor risks include perceptions of re-pricing management’s earlier awards, possible windfalls if the stock appreciates quickly post-exchange, and the dilutive effect if many participants exercise options; however, the Board’s structure of exchange ratios and share recapture aims to mitigate these concerns. A sophisticated analyst should evaluate the modeling behind exchange ratios, the sensitivity of dilution and overhang metrics to participation rates, the Company’s rationale for the $18 threshold and two-year full-term requirement, and how the exchanges fit with broader retention and long-term incentive strategy given the Company’s clinical-stage profile and near-term regulatory and milestone catalysts.

This management proposal mirrors Proposal 4 but is targeted at executive employees (president and EVPs) and is motivated by the Company’s need to retain highly specialized leadership with critical gene therapy expertise. The Board and Compensation Committee emphasize that executives hold a material portion of outstanding options and excluding them could undermine retention objectives; accordingly, exchange mechanics (eligibility thresholds, two-year required outstanding period, tiered exchange ratios based on grant date/exercise price groups) are similar to the non-executive program but applied to a much smaller participant pool. Replacement options vest over two years and carry an eight-year term; exchange ratios were determined with an outside advisor using Black‑Scholes to aim for approximate fair-value neutrality and to reduce net overhang (management estimates 1,294,004 net shares surrendered if fully subscribed by executives). The proposal raises classic governance trade-offs: while the exchange reduces overhang and restores incentive value, critics may view it as re-pricing historic grants to executives (potentially rewarding prior grant timing), and proxy advisors may scrutinize participation by named executives and the impact on pay-for-performance. Management counters that the program is voluntary, structured, and accompanied by limits (e.g., eligibility windows, tender-offer rules), and that accounting and tax treatment are expected to be manageable and non-material; incremental expense will be measured and recognized over vesting. A sophisticated analyst should examine the exchange ratios and modeling assumptions, the specific executives and awards likely to participate, post-exchange dilution scenarios under varying participation rates, and alignment with other retention tools (cash incentives, PSUs) given the Company’s stage and upcoming regulatory milestones. The Board’s unanimous recommendation reflects its view that the program balances retention needs and shareholder interests by recapturing surrendered shares for future grants and capping immediate dilution while realigning pay incentives.

This is a catch-all, procedural proposal included in the Notice to allow the meeting to consider any other valid matters that may arise. It does not request shareholder approval of a specific substantive action and typically gives the Board-appointed proxies discretion to vote on unexpected items consistent with shareholders’ best interests. From a governance perspective, such items are rare at well-managed companies and normally consist of ministerial or timing-related actions, ratifications of procedural matters, or new business requiring no immediate binding action. Because no specific action is proposed, investors cannot meaningfully evaluate potential effects in advance; however, the Company’s solicitation materials indicate proxies will use their judgment on such matters, and any significant matter would likely be followed by formal disclosure and, if required, a separate shareholder vote in due course. Analysts should note that the presence of this proposal does not change the substance of the five enumerated voting matters and is standard practice to ensure proper meeting conduct. The absence of a board recommendation indicates the Board expects no material issues beyond the listed proposals, but stockholders should monitor meeting reports and any Form 8‑K for disclosures if other matters are raised. Overall, this item presents no targeted governance risk absent a specific proposal surfaced at the meeting.